The Latest Headlines at American Banking and Market News
Expedia Group (NASDAQ:EXPE) Price Target Cut to $132.00 by Analysts at HSBC
Expedia Group (NASDAQ:EXPE – Free Report) had its price target reduced by HSBC from $166.00 to $132.00 in a research report released on Tuesday, Benzinga reports. HSBC currently has a hold rating on the online travel company’s... More of this article »
Esperion Therapeutics (NASDAQ:ESPR) Given “Buy” Rating at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. Needham & Company LLC currently... More of this article »
EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $30.00 by Analysts at Mizuho
EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) had its price objective decreased by Mizuho from $39.00 to $30.00 in a research note issued to investors on Tuesday morning, Benzinga reports. Mizuho currently has a buy rating... More of this article »
Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $22.00 Price Target at JMP Securities
Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) had its price target decreased by JMP Securities from $23.00 to $22.00 in a research report sent to investors on Tuesday, Benzinga reports. JMP Securities currently has a market... More of this article »
Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $27.00 by Analysts at HC Wainwright
Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) had its target price cut by HC Wainwright from $28.00 to $27.00 in a research report released on Tuesday morning, Benzinga reports. They currently have a buy rating on the biotechnology... More of this article »
Design Therapeutics (NASDAQ:DSGN) Upgraded to Overweight at Piper Sandler
Piper Sandler upgraded shares of Design Therapeutics (NASDAQ:DSGN – Free Report) from a neutral rating to an overweight rating in a research note issued to investors on Tuesday morning, MarketBeat.com reports. The firm currently... More of this article »
Eledon Pharmaceuticals (NASDAQ:ELDN) Price Target Raised to $16.00 at HC Wainwright
Eledon Pharmaceuticals (NASDAQ:ELDN – Free Report) had its price target increased by HC Wainwright from $13.00 to $16.00 in a report released on Tuesday, Benzinga reports. They currently have a buy rating on the stock. Eledon... More of this article »
Datadog’s (DDOG) “Buy” Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reiterated their buy rating on shares of Datadog (NASDAQ:DDOG – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $165.00 price objective... More of this article »
Cytosorbents (NASDAQ:CTSO) Receives “Neutral” Rating from HC Wainwright
HC Wainwright restated their neutral rating on shares of Cytosorbents (NASDAQ:CTSO – Free Report) in a report published on Tuesday, Benzinga reports. HC Wainwright currently has a $1.00 price target on the medical research company’s... More of this article »
Day One Biopharmaceuticals (NASDAQ:DAWN) Given “Buy” Rating at Needham & Company LLC
Needham & Company LLC restated their buy rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) in a report issued on Tuesday morning, Benzinga reports. They currently have a $33.00 price objective on... More of this article »
Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $40.00 Price Target at HC Wainwright
Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) had its price objective trimmed by HC Wainwright from $50.00 to $40.00 in a research report report published on Tuesday, Benzinga reports. They currently have a buy rating... More of this article »
Corvus Pharmaceuticals (NASDAQ:CRVS) Given New $8.00 Price Target at Oppenheimer
Corvus Pharmaceuticals (NASDAQ:CRVS – Free Report) had its target price lifted by Oppenheimer from $7.00 to $8.00 in a research report sent to investors on Tuesday, Benzinga reports. Oppenheimer currently has an outperform rating... More of this article »
Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Increased to $97.00 by Analysts at Piper Sandler
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target raised by Piper Sandler from $56.00 to $97.00 in a research report report published on Tuesday, Benzinga reports. Piper Sandler currently has an overweight... More of this article »